Skip to main content
THC BIOMED INTERNATIONAL LIMITED logo

THC BIOMED INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · THC ISIN · CA87243W1032 LEI · 529900LOF9A0UPDYZT54 CSE Manufacturing
Open in API
Filings indexed 452 across all filing types
Latest filing 2025-08-26 Regulatory Filings
Country CA Canada
Listing CSE THC

About THC BIOMED INTERNATIONAL LIMITED

https://thcbiomed.com/

THC BioMed International Ltd. is a federally licensed producer and supplier of legal cannabis for both medical and recreational markets. The company specializes in cultivating high-quality, BC indoor-grown cannabis, emphasizing organic growing methods, pure nutrients, and the exclusion of pesticides. Key product offerings include dry flower (Indica, Sativa, Hybrid), pre-rolls (such as Glass Joints and Dragon's Breath), concentrates (ICE Bubble Hash), and infused products like beverage shots and edibles. THC BioMed also operates in the life sciences sector, providing research, development, and plant innovation services, including the supply of cannabis genetics under the CloneWorld brand. The company utilizes traditional HID lighting techniques to ensure product potency and quality, and offers consulting services to other licensed producers.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2025-08-26 English
News release - English.pdf
Regulatory Filings
2025-08-21 English
News release - English.pdf
Capital/Financing Update Classification · 73% confidence The document is a press release announcing the completion of a sale-leaseback of real estate assets (two strata units) to raise cash for the company’s debt and working capital. This constitutes a financing activity and capital structure update rather than a regulatory filing, proxy, dividend notice, or routine earnings report. Hence, it falls under the Capital/Financing Update category.
2025-06-06 English
News release - English.pdf
Capital/Financing Update Classification · 75% confidence The document is a press release by THC BioMed announcing the sale of two property units (a sale‐leaseback transaction) to generate proceeds for working capital and debt payment. This is a corporate financing activity (sale‐leaseback) rather than a dividend, share issuance, director dealing, or regulatory report. It is not a full financial statement, earnings release, or governance document. It best fits the “Capital/Financing Update” category as it describes the company’s capital structure activity and use of proceeds.
2025-05-30 English
News release - English.pdf
Capital/Financing Update Classification · 72% confidence The document is a corporate press release announcing the closing of a property sale (strata units) and the use of proceeds for working capital. This is not an Annual Report, earnings release, M&A transaction, share issue, or other specific category. It represents a financing-related update (sale of assets to raise funds). Therefore, it best fits CAPITAL/FINANCING UPDATE (CAP).
2025-05-06 English
News release - English.pdf
Regulatory Filings
2025-02-14 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.